Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
April 26 2023 - 10:08AM
Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical
company focused on modality-agnostic targeted oncology therapies,
today announced that the first clinical data from its Phase 1
clinical study of CLN-619 in patients with advanced solid tumors
will be presented at the 2023 American Society of Clinical Oncology
(ASCO) Annual Meeting taking place in Chicago from June 2-6.
“We are pleased to present our initial clinical
findings for CLN-619 at ASCO 2023. CLN-619 is a novel, potential
first-in-class antibody that binds to MICA and MICB, stress-induced
ligands that engage the activating receptor NKG2D present on both
innate and adaptive immune cells. MICA and MICB are expressed on a
wide variety of solid tumors and hematological malignancies, and we
believe CLN-619 has potential to treat a range of tumors,” said
Jeffrey Jones, MD, MPH, MBA, Chief Medical Officer, Cullinan
Oncology.
The details of the presentation include:
Poster Title: A phase 1 dose-escalation study
to investigate the safety, efficacy, pharmacokinetics, and
pharmacodynamic activity of CLN-619 (Anti-MICA/B antibody) alone
and in combination with pembrolizumab in patients with advanced
solid tumors.
Author: Dr. Judy Wang, et
al.
Poster Number: 2532
Session: Developmental
Therapeutics—Immunotherapy
Session Date and Time: June 3, 2023, 8:00
AM-11:00 AM Central Time
About CLN-619CLN-619 is a potential
first-in-class humanized IgG1 monoclonal antibody that binds to the
stress induced ligands, MICA and MICB, which are expressed on a
wide variety of solid tumors and hematological malignancies.
Engagement of MICA/B by the activating receptor NKG2D, present on
both cytotoxic innate and adaptive immune cells, results in target
cell lysis. However, tumor cells can shed MICA/B via proteases they
release into the tumor microenvironment, resulting in evasion of
immune-mediated destruction. CLN-619 functions by restoring MICA/B
expression on the surface of tumor cells, enhancing the interaction
between MICA and NKG2D, and inducing antibody-dependent cellular
toxicity (ADCC), together promoting anti-tumor activity via
multiple immune-mediated mechanisms. CLN-619 is being studied in an
ongoing Phase 1 clinical trial both as a monotherapy and in
combination with pembrolizumab. The study design allows dose level
extensions as well as expansion in tumor-specific cohorts.
About Cullinan OncologyCullinan Oncology,
Inc.(NASDAQ: CGEM) is a biopharmaceutical company dedicated to
creating new standards of care for patients with cancer. We
innovate without borders to find the most promising clinic-ready
cancer therapies, whether from our own discovery efforts or through
exceptional engagement with our academic and industry partners.
Anchored in a deep understanding of immuno-oncology and
translational cancer medicine, we leverage our scientific
excellence in small molecules and biologics to create
differentiated ideas, identify unique targets, and select the
optimal modality to develop transformative therapeutics across
cancer indications. Powered by our novel research model, we push
conventional boundaries from candidate selection to cancer
therapeutic, applying rigorous early experimentation to fast-track
only the most promising assets to the clinic and ultimately
commercialization. As a result, our diversified pipeline is
strategically built with assets that activate the immune system or
inhibit key oncogenic drivers across a wide range of modalities,
each with the potential to be the best or first in their class.
Our people possess deep scientific expertise, seek innovation
openly, and exercise creativity and urgency to deliver on our
promise to bring new therapeutic solutions to patients with cancer.
Learn more about our Company at www.cullinanoncology.com, and
follow us on LinkedIn and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, express
or implied statements regarding Cullinan’s beliefs and expectations
regarding the potential benefits and therapeutic potential of
CLN-619; our clinical development plans and timelines; our plans
regarding future data presentations and other statements that are
not historical facts. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “target,” “should,”
“would,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Any forward-looking statements in this press release are based
on management's current expectations and beliefs of future events
and are subject to known and unknown risks and uncertainties that
may cause our actual results, performance or achievements to be
materially different from any expressed or implied by the
forward-looking statements. These risks include, but are not
limited to, the following: uncertainty regarding the timing and
results of regulatory submissions; success of our clinical trials
and preclinical studies; risks related to our ability to protect
and maintain our intellectual property position; risks related to
manufacturing, supply, and distribution of our product candidates;
risks related to the impact of COVID-19 affecting countries or
regions in which we have operations or do business, including
potential negative impacts on our employees, customers, supply
chain and production as well as global economies and financial
markets; the risk that any one or more of our product candidates,
including those that are co-developed, will not be successfully
developed and commercialized; the risk that the results of
preclinical studies or clinical studies will not be predictive of
future results in connection with future studies; and success of
any collaboration, partnership, license or similar agreements.
These and other important risks and uncertainties discussed in our
filings with the Securities and Exchange Commission, including
under the caption “Risk Factors” in our most recent Annual Report
on Form 10-K and subsequent filings with the SEC, could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. While we may
elect to update such forward-looking statements at some point in
the future, we disclaim any obligation to do so, even if subsequent
events cause our views to change, except to the extent required by
law. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release. Moreover, except as required by law, neither
Cullinan nor any other person assumes responsibility for the
accuracy and completeness of the forward-looking statements
included in this press release. Any forward-looking statement
included in this press release speaks only as of the date on which
it was made.
Contacts:
Investor RelationsChad Messer+1
203.464.8900cmesser@cullinanoncology.com
MediaRose Weldon+1 215.801.7644rweldon@cullinanoncology.com
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jul 2023 to Jul 2024